Bill Gates Applauds Nobel Laureates Katalin Kariko And Drew Weissman Behind Revolutionary mRNA COVID-19 Vaccines

Tech visionary Bill Gates commended the groundbreaking work of Nobel Prize laureates Katalin Kariko and Drew Weissman, whose research on mRNA has revolutionized vaccine development against COVID-19.

What Happened: Gates took to X, formerly Twitter, to acknowledge the work of scientists Kariko and Weissman. He celebrated their pioneering research on messenger-RNA (mRNA), which led to the development of lifesaving vaccines against COVID-19 and earned them this year’s Nobel Prize in medicine.

He stated, “@kkariko and @WeissmanLab saw the potential of mRNA when few others did and fought tooth and nail to study it—resulting in revolutionary vaccines that have saved tens of millions of lives. Congratulations on your well-deserved Nobel Prize; your work has truly changed the world.”

See Also: Tar In Cannabis Smoke: Is There A Link Between Smoking Weed And Cancer?

Why It Matters: The work of Kariko and Weissman has had a monumental impact on global health. Their research allowed companies like Moderna Inc. and Pfizer Inc.– BioNTech SE partnership to create mRNA-based vaccines. These vaccines have been administered to hundreds of millions of people worldwide in the fight against the COVID-19 pandemic.

Read Next: Biden’s Urgent Action Against Antibiotic-Resistant Bacteria

Photo by Frederic Legrand – COMEO on Shutterstock


Engineered by Benzinga Neuro, Edited by Pooja Rajkumari


The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMediaGeneralBill GatesDrew WeissmanKatalin KarikomRNA VaccineNobel Prize
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!